🎉 M&A multiples are live!
Check it out!

PolyPid Valuation Multiples

Discover revenue and EBITDA valuation multiples for PolyPid and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

PolyPid Overview

About PolyPid

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.


Founded

2008

HQ

United States of America
Employees

60

Website

polypid.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$20.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

PolyPid Financials

PolyPid has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, PolyPid achieved revenue of n/a and an EBITDA of -$26.4M.

PolyPid expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See PolyPid valuation multiples based on analyst estimates

PolyPid P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$20.4M -$26.4M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$39.6M -$23.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $3.0M $5.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

PolyPid Stock Performance

As of April 15, 2025, PolyPid's stock price is $3.

PolyPid has current market cap of $26.0M, and EV of $20.0M.

See PolyPid trading valuation data

PolyPid Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$20.0M $26.0M XXX XXX XXX XXX $-4.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

PolyPid Valuation Multiples

As of April 15, 2025, PolyPid has market cap of $26.0M and EV of $20.0M.

PolyPid's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate PolyPid's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for PolyPid and 10K+ public comps

PolyPid Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $20.0M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.8x XXX XXX XXX
P/E -0.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PolyPid Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

PolyPid Valuation Multiples

PolyPid's NTM/LTM revenue growth is Infinity%

PolyPid's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, PolyPid's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate PolyPid's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for PolyPid and other 10K+ public comps

PolyPid Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 30% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

PolyPid Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

PolyPid M&A and Investment Activity

PolyPid acquired  XXX companies to date.

Last acquisition by PolyPid was  XXXXXXXX, XXXXX XXXXX XXXXXX . PolyPid acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by PolyPid

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About PolyPid

When was PolyPid founded? PolyPid was founded in 2008.
Where is PolyPid headquartered? PolyPid is headquartered in United States of America.
How many employees does PolyPid have? As of today, PolyPid has 60 employees.
Who is the CEO of PolyPid? PolyPid's CEO is Ms. Dikla Czaczkes Akselbrad.
Is PolyPid publicy listed? Yes, PolyPid is a public company listed on NAS.
What is the stock symbol of PolyPid? PolyPid trades under PYPD ticker.
When did PolyPid go public? PolyPid went public in 2020.
Who are competitors of PolyPid? Similar companies to PolyPid include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of PolyPid? PolyPid's current market cap is $26.0M
Is PolyPid profitable? Yes, PolyPid is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.